Predict your next investment

HEALTHCARE | Pharmaceuticals / Drugs
agrx.net

See what CB Insights has to offer

Founded Year

2000

Stage

Loan | Alive

Total Raised

$3M

Last Raised

$250K | 2 yrs ago

About A&G Pharmaceutical

A&G Pharmaceutical is a theranostics company creating and developing monoclonal antibodies to cancer-specific targets as a basis for novel therapeutic and diagnostic products. A&G's therapeutics division is pursuing development of anti-GP88 and other monoclonal antibody drugs for cancer. On the diagnostics side, A&G is currently developing test kits that will improve early detection, diagnosis, and treatment of breast cancer based on GP88. One of these'"a biopsy test kit currently in clinical trials'"will also serve as a companion diagnostic to anti-GP88 immunotherapy. A&G's Precision Antibody'„ service unit generates revenue to fund the drug development effort by accelerating the creation of novel, customized antibodies for leading pharmaceutical and biotechnology companies as well as federal laboratories. A&G has raised $5.5 million of equity capital and is located in Columbia, Md.

A&G Pharmaceutical Headquarter Location

9130 Red Branch Road Suite U

Columbia, Maryland, 21045,

United States

410-884-4100

Latest A&G Pharmaceutical News

Identification Of An Internalizing Cancer Target For Novel Antibody Drug Conjugate By A&G Pharmaceutical And Precision Antibody Researchers.

Jun 7, 2021

agpharma.com ) and Precision Antibody ( www.precisionantibody.com ) are pleased to announce the publication, in PLOS One, of their collaborative study regarding the identification of Prostaglandin F2 receptor negative regulator as an internalizing  cancer cell target and the isolation of proprietary internalizing antibody for antibody drug conjugate development. A&G Pharmaceutical is a theranostic target discovery company developing therapeutic and diagnostic products in Oncology. Precision Antibody has developed a customized program to select internalizing antibodies for cell surface targets. This includes a strategized antigen design and immunization program with high throughput targeted screening of internalizing antibodies, clone selection and functional assays. Antibody-Drug Conjugates (ADCs) have recently received increased interest as therapeutic choices in oncology. ADCs are composed of a monoclonal antibody binding to a cell surface target, a linker, and a cytotoxic payload. After binding to its antigen, the mAb induces endocytosis, shuttling the payload inside the cell. Several ADCs have been approved by the Food and Drug Administration as treatment for hematopoietic and solid tumors. The approach centered on the identification of targets internalized and expressed on cancer cells by screening hybridoma libraries developed against cancer cell-surface antigens. Antibody libraries are screened for their ability to bind, internalize, and deliver a cytotoxic payload to specific cancer cells. This approach was used by A&G Pharmaceutical and Precision Antibody to characterize an internalizing monoclonal antibody, identify its target by mass spectrometry as PTGFRN and shows its efficacy as ADC  in vitro and in vivo, for several cancer types including head and neck cancers and spindle cell carcinoma. PTGFRN is a member of cell surface tetraspanins family contributing to many key biological functions linked to adhesion, migration and survival and show promise as therapeutic targets. "We are delighted to have identified PTFGRN as a promising internalizing cancer target that could increase the repertoire of therapeutic options for cancers with unmet needs. After developing diagnostic and therapeutic products for progranulin/GP88, it is exciting to contribute new cancer therapeutic options based on cell-surface protein" declared Dr. Ginette Serrero, A&G Pharmaceutical CEO. For Dr. Jun Hayashi, Precision Antibody President "knowing that Precision internalizing antibody development program led to the discovery of new targeted cancer therapy is rewarding". This study is found in https://journals.plos.org/plosone/article/authors?id=10.1371/journal.pone.0246197 Contact information: kdoubleday@precisionantibody.com . 410-884-4100

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing A&G Pharmaceutical

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

A&G Pharmaceutical is included in 3 Expert Collections, including Cancer.

C

Cancer

1,179 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

B

Biopharmaceuticals

5,882 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

R

Regenerative Medicine

1,767 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

A&G Pharmaceutical Patents

A&G Pharmaceutical has filed 14 patents.

The 3 most popular patent topics include:

  • Clusters of differentiation
  • Immunology
  • Immune system
patents chart

Application Date

Grant Date

Title

Related Topics

Status

8/29/2011

12/16/2014

Molecular biology, Transcription factors, Nucleic acids, Biotechnology, Genetics

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

8/29/2011

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

12/16/2014

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Molecular biology, Transcription factors, Nucleic acids, Biotechnology, Genetics

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.